- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03122782
Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy
Study Design:
Randomized Controlled Clinical Trial.
Study Population:
The study population will be a consecutive series of participants attending the Early Cancer Detection Unit (ECDU) at Ain Shams University Maternity Hospital.
80 women who are scheduled to undergo a hysteroscopic myomectomy will be included and will be randomized into two groups:
Group A: women will undergo a hysteroscopic myomectomy with the use of (TXA) Kapron in the distention medium
Group B: women will undergo hysteroscopic myomectomy with the use of placebo(normal saline in the distention medium).
Randomization will be performed using a Computer-generated randomization system.
The allocated groups will be concealed in serially-numbered sealed opaque envelopes that will only be opened after recruitment.
Patient allocation will be performed prior to the induction of anesthesia by an independent person, who will not otherwise be involved in this study.
The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium.
Therefore, this study will be a randomized double blind prospective clinical
Methodology:
- Informed written consent obtained from the participant.
History
- Personal history
- Menstrual history
- Detailed obstetric history
- Surgical intervention especially uterine surgeries and any post-operative complication
- History of drug intake, especially hormonal treatment or anticoagulant therapy.
- Routine preoperative investigations in addition to a serum pregnancy test if pregnancy is suspected.
- Physical examination including general, abdominal and pelvic examination.
- Hysteroscopy will be performed in the early proliferative phase using normal saline as a distention medium.
Only in intervention group (TXA group) KAPRON (Tranexamic acid) will be added to the injected media.
- In intervention group 500 mg of Kapron for every 500 ml of distending media will be added.
- In the control group, placebo .i.e. ,normal saline in the same form will be injected inside every 500 ml of the distention medium.
- The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium. Therefore, our study will be a randomized double blind prospective clinical trial.
- Intraoperative bleeding and quality of view will be observed.
- A blood sample will be taken from each participant in both groups after 24 hours from the end of the operation for both hemoglobin and hematocrit levels.
Types of outcome measures:
Primary outcome measures:
Estimated Blood loss defined as comparing the hematocrit and hemoglobin at base line (preoperative ) and 24 hours after surgery with the Tranexamic acid compared to the control group.
Secondary outcome measures:
The quality of view, duration of surgery, the volume of injected media, intraoperative complications and the success of the completion of the operation will be secondary outcomes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Radwa Ali Rasheedy, MD
- Phone Number: 01283492979
- Email: Radwaebed@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be able to understand, and read and sign the study specific informed consent after fully explanation the nature of the study .
- Subjects exhibit submucous myoma that are completely within the endometrial cavity or extend less than 50 percent into the myometrium (type 0,i)according to European Society Of Hysteroscopy (ESH).
- The submucous myoma are less than 4 cm in diameter
Exclusion Criteria:
- Pregnancy
- Active Pelvic Infection
- Present or History of Cervical or Uterine Caner
- Bleeding Diathesis or patient on anticoagulant
- Contraindication and /or allergy to medication specified in the treatment protocol
- History of ischemic heart disease
- Patient with Cardiopulmonary, Hepatic , and renal diseases
- Patient with metabolic disorders including diabetes
- Patients with uterine septum or structural abnormality
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Tranexamic acid (TXA) Group
Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.
|
Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
Other Names:
|
Placebo Comparator: Normal Saline (control group)
Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.
|
5ml of normal saline will be added to every 500 ml of distension media
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated blood loss by comparing changes in hemoglobin level
Time Frame: 24 Hours
|
Estimated blood loss by comparing changes in hemoglobin level before hysteroscopic myomectomy (preoperative) and 24 hours after hysteroscopic myomectomy (postoperative) in Tranexamic acid group comparing to the control group
|
24 Hours
|
Estimated blood loss by comparing changes in hematocrit level
Time Frame: 24 hours
|
Estimated blood loss by comparing changes in hematocrit level before hysteroscopic myomectomy (preoperative) and 24 hours after hysteroscopic myomectomy (postoperative) in the Tranexamic acid group comparing to the control group
|
24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ahmed Khairyy Makled, MD, ain shams University
- Study Chair: Amgad Said Abu-Gamra, MD, ain shams University
- Study Director: Radwa Ali Rasheedy, MD, ain shams University
- Principal Investigator: Hajer Giuma Soliman, M.B.B.CH, ain shams University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASU-2016-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgical Blood Loss
-
The University of Texas Health Science Center at...RecruitingMyomectomy; Surgical Blood LossUnited States
-
Assiut UniversityCompletedHepatectomy, Surgical Blood Loss, TerlipressinEgypt
-
Northwell HealthCompletedSurgical Blood LossUnited States
-
i-SEPCompletedHemorrhage | Blood Loss | Surgical Blood LossFrance
-
CSL BehringCompletedSurgical Blood Loss | Postoperative Blood LossUnited Kingdom, Canada, Japan, Italy, Poland, Germany, Czech Republic, Austria, Brazil, Denmark, Finland
-
Cubist Pharmaceuticals LLCCompletedSurgical Procedures, Operative | BloodlossGermany, Poland, United States
-
University Health Network, TorontoThe Physicians' Services Incorporated FoundationCompletedTotal Knee Arthroplasty | Surgical Blood LossCanada
-
Cubist Pharmaceuticals LLCCompletedSurgical Procedures, Operative | BloodlossUnited States, Canada
-
Population Health Research InstituteCompletedBleeding | Surgical Blood LossCanada
-
Australian and New Zealand Intensive Care Research...Australian Red CrossActive, not recruiting
Clinical Trials on Topical application Tranexamic acid
-
Assiut UniversityCompleted
-
Indonesia UniversityActive, not recruiting
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
Samsung Medical CenterUnknownBleeding | Transfusion Related ComplicationKorea, Republic of
-
Hospital for Special Surgery, New YorkCompletedOsteoarthritis, KneeUnited States
-
Hospital for Special Surgery, New YorkMayo ClinicCompletedOsteoarthritisUnited States
-
Centro Dermatológico Dr. Ladislao de la PascuaUnknownMelanosis | Melasma | ChloasmaMexico
-
Icahn School of Medicine at Mount SinaiRecruiting
-
Florence Nightingale Hospital, IstanbulCompletedRotator Cuff Tears | Rotator Cuff Rupture | Tranexamic Acid | Shoulder Arthroscopy | Visual ClarityTurkey
-
University Health Network, TorontoNot yet recruitingDistal Radius FracturesCanada